期刊文献+

胃癌生长抑素受体mRNA表达的研究 被引量:8

Study on mRNA expressions of subtypes of somatostatin receptors in gastric carcinoma
下载PDF
导出
摘要 目的:研究胃癌组织中生长抑素受体(SSTR)各亚型的分布与表达特性。方法:用逆转录聚合酶链反应(RT-PCR)检测24例胃癌肿瘤组织与癌旁正常组织中5种SSTR亚型mRNA的表达。结果:胃癌肿瘤组织及癌旁组织中SSTR1、2、5mRNA阳性表达率均为100%(24/24);SSTR3、4mRNA在肿瘤组织的阳性表达率分别为79%(19/24)和71%(17/24),在癌旁组织的阳性表达率分别为83%(20/24)和75%(18/24)。RT-PCR产物凝胶定量分析结果表明胃癌肿瘤组织各型生长抑素受体mRNA的表达量均较癌旁组织为低,但差异无统计学意义,P>0·05。胃癌肿瘤组织中以SSTR2mRNA表达量最高,其次为SSTR5、SSTR1、SSTR3mRNA,SSTR4mRNA表达量最低。结论:胃癌肿瘤组织中存在5种生长抑素受体亚型的表达,并以SSTR2的表达最为显著。 OBJECTIVE: To study the expression and distribution of 5 subtypes of somatostatin receptors (SSTR1-5) in gastric carcinoma. METHODS: The mRNA expressions of SSTR1-5 in central and adjacent tissues of gastric carcinoma were detected by RT-PCR technique, RESULTS:Positive expression rates of SSTR1, SSTR2 and SSTR5 mRNA were 100% in central and adjacent tissues of gastric carcinoma, while SSTR3 and SSTR4 mRNA were 790/00 and 71% in central tissue and 83% and 75% in adjacent tissue of gastric carcinoma, respectively. The mRNA expressions of 5 SSTR in tumor tissue were lower than whose in adjacent tissue, but there was no significant difference between central and adjacent tissues ', P 〉 0. 05. CONSLUSION:There is mRNA expressions of 5 subtypes of somatostatin receptors in gastric carcinoma, and the mRNA expression of SSTR2 is higher than that of the others.
出处 《中华肿瘤防治杂志》 CAS 2006年第7期498-500,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 胃肿瘤 受体 生长抑素 RNA 信使 基因表达 gastric neoplasm receptors, somatostatin RNA, messenger gene expression
  • 相关文献

参考文献8

  • 1汪静,邓敬兰.生长抑素受体家族与肿瘤[J].细胞与分子免疫学杂志,1998,14(4):318-320. 被引量:1
  • 2Maria C, Zatelli, Federico Tagliati, et al. somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyuoid carcinoma cell line TT [J]. The Journal of Clinical endocrinology & metabolism,2001,86(5):2161-2169.
  • 3丁丽,姜藻.生长抑素类似物基因治疗恶性肿瘤展望[J].国外医学(肿瘤学分册),2002,29(4):272-274. 被引量:3
  • 4Chen X J, Liu Z S, Qian Q. Study of Octreotide inhibit growth and induce apoptosis of human hepatocellular carcinoma cell[J].Clin J Hepatobiliary Surg, 2000, 6(8): 146-147.
  • 5Jia W O, Xu Q L, Xu R N, et al. Octreotide acts as an antitumot angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts[J]. Comcer Res clin Oncol, 2003, 129(6):327-334.
  • 6Patel Y, Srikant C B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptor (hsstr 1-5)[J].Endocrinology, 1994,135(6) :2814-2817.
  • 7Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatiin receptor types in 81 cases of gastrointestinal and pancreatic endocrine tumors[J]. Virchows Archive, 2002,440 (5):461-475.
  • 8Kouroumalis E,Skordilis P,Thermos K,et al. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study[J]. Gut,1998,42(3):442-447.

二级参考文献18

  • 1林汉,国外医学.放射医学核医学分册,1996年,20卷,3期,97页
  • 2赵利军,国外医学.放射医学核医学分册,1996年,20卷,3期,121页
  • 3Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone(GH) from octreotide-resistant human GHsecreting adenomas[J]. J Clin Endocrinol Metab, 2001, 86(1): 140-145.
  • 4Ferone D, van Hagen MP, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro[J]. J Clin Endocrinol Metab, 2000, 85(4): 1719-1726.
  • 5Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo[J]. Int J Oncol, 2000, 16(6): 1197-1201.
  • 6O'Byrne KJ, Schally AV, Thomas A, et al. Somatostatin, its receptors and analogs, in lung cancer[J]. Chemotherapy, 2001, 47(Suppl2): 78-108.
  • 7Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs[J]. Proc Soc Exp Biol Med, 1998, 217(2): 143-152.
  • 8Charland S, Boucher MJ, Houde M, et al. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein(MAP) kinase activation in normal and tumoral pancreatic acinar cells[J]. Endocrinology, 2001, 142(1): 121-128.
  • 9Giannetti N, Enjalbert A, Krantic S. Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation[J]. J Cell Biochem, 2000, 78(4): 666-673.
  • 10Lachowicz Ochedalska A, Rebas E, Kunert Radek J, et al. Effects of somatostatin and its analogues on tyrosine kinase activity in rodent tumors[J]. Biol Signals Recept, 2000, 9(5): 255-259.

共引文献2

同被引文献66

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部